Loading...
XSHE
002868
Market cap805mUSD
Dec 05, Last price  
36.64CNY
1D
-0.57%
1Q
38.47%
IPO
109.78%
Name

Lifecome Biochemistry Co Ltd

Chart & Performance

D1W1MN
XSHE:002868 chart
P/E
P/S
8.77
EPS
Div Yield, %
Shrs. gr., 5y
-0.06%
Rev. gr., 5y
16.41%
Revenues
649m
+28.08%
306,555,594297,150,634295,776,106385,613,322401,490,366375,411,280344,291,893303,759,977308,145,259363,386,382329,850,238507,004,856649,373,107
Net income
-445m
L+100.55%
43,240,61532,970,23331,449,37078,104,64592,360,69885,924,98974,689,44656,966,03243,208,31500-221,817,878-444,864,018
CFO
141m
P
60,915,16577,678,72062,759,716127,107,974135,407,94796,109,55983,697,14174,087,74290,720,87435,170,4180-186,758,867141,406,585
Dividend
May 21, 20210.14 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It primarily offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, natamycin products, etc. The company was founded in 2003 and is based in Pucheng, China.
IPO date
May 03, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT